Furin‐Mediated Intracellular Aggregation of Radioactive Molecules for Enhanced Radionuclide Imaging and Tumor Therapy
Researchers have engineered a furin‑responsive radioactive probe, RVRR‑TPE, that self‑assembles into nanoparticles inside furin‑positive cancer cells. The molecule couples a furin‑cleavable Arg‑Val‑Arg‑Arg peptide, an aggregation‑induced emission fluorophore (tetraphenylethene), and a phenol group for iodine‑125/131 labeling. In mouse models, the 125I/131I‑labeled probe produces strong SPECT signals and significantly slows growth of HCT116 colon tumors. This approach offers a novel way to boost tumor retention of radiopharmaceuticals for both imaging and therapy.
STAT+: Even at a Meeting in Rome, FDA Shifts Are Top of Mind for Gene Therapy Field
At a gene‑therapy summit in Rome, Tim Hunt highlighted recent FDA approvals of rare‑disease treatments from Rocket Pharmaceuticals and Regeneron as signs of progress. He also flagged the departure of Vinay Prasad, the FDA’s top regulator for cell and gene therapies,...
Caris Launches Caris MI Clarity for AI-Powered Breast Cancer Recurrence Risk Assessment
Caris Life Sciences has introduced Caris MI Clarity, an AI‑driven prognostic test that evaluates both early (0‑5 years) and late (5‑15 years) distant recurrence risk for postmenopausal patients with HR‑positive/HER2‑negative, node‑negative early‑stage breast cancer. The assay analyzes digitized H&E pathology...
Hierarchically Multifunctional Fiber‐optic Theranostic Probe for Cancer Photothermal‐photodynamic Synergism
Researchers have created a hierarchically multifunctional fiber‑optic probe that simultaneously measures dissolved oxygen and delivers combined photothermal‑photodynamic therapy. The three‑layer architecture isolates an Ru(dpp) oxygen sensor, an ICG photosensitizer, and a CaO2@LA oxygen‑generating layer, eliminating optical crosstalk and counteracting tumor...
Multi4 Medical Receives CE Mark Approval for Multi4 System to Perform Outpatient Bladder Cancer Treatment
Multi4 Medical has secured CE mark approval for its Multi4 System, an integrated endoscopic platform that enables bladder cancer treatment in a single outpatient visit. The device delivers local anesthesia, performs tumor resection, extracts tissue for pathology, and cauterizes—all without...
Microbiome Explorer Challenge Returns Seeking Europe’s Next Microbiome Start-Up Stars
The Microbiome Explorer Challenge (MEC) returns for its 2026 edition, expanding from a Central‑Eastern European focus to cover the entire continent. It invites pre‑seed, seed‑stage startups and research spin‑outs to submit market‑ready concepts for personalized microbiome modulation across gut, skin,...
With Large DNA Fragment Assembly, Scientists Can Design Microbes that Produce Countless Complex Products
A new review in Quantitative Biology shows scientists can now reliably assemble very large DNA fragments, enabling the construction of whole metabolic pathways and even extra chromosomes inside microbes. This capability turns yeast and bacteria into efficient cell factories that...
Popular GLP-1 Drugs Significantly Reduce Major Cardiovascular Events,
A systematic review and meta‑analysis of eleven cardiovascular outcome trials involving 91,490 high‑risk patients found that GLP‑1 receptor agonists reduce major adverse cardiovascular events (MACE) by 14% compared with placebo. The therapy also lowered cardiovascular mortality by 13% and improved...
Bacteria: Unsung Players in the Tumor Microbiome
Recent consensus research highlights that every tumor harbors its own low‑biomass microbiome, influencing cancer development, metastasis, and treatment response. Researchers, led by Maria Rescigno, emphasize the need for rigorous detection methods—favoring 16S rRNA sequencing and culturomics—to distinguish genuine microbes from...
World's First Vaccine for Lyme Disease Could Be Available in 2027
Pfizer and French partner Valneva announced that their Lyme disease vaccine candidate PF‑07307405 (LB6V) achieved 73.2% efficacy in Phase III trials involving more than 9,000 participants. Although the study missed its primary statistical endpoint due to a low incidence of cases,...
EyePoint Inc (EYPT) Q1 2026 Earnings Call Transcript
EyePoint Pharmaceuticals reported a dramatic revenue drop to $600,000 for the quarter, reflecting the reversal of deferred YUTIQ license revenue, while operating expenses surged to $71 million as Phase 3 trials for its DuraVu platform intensified. The company posted a net loss...
Vanda Pharmaceuticals Inc (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals reported Q1 2026 net product sales of $51.7 million, a modest 3% year‑over‑year increase driven primarily by a 26% surge in Fanapt revenue and a 32% rise in prescriptions. Hetlioz sales continued to decline, falling 24% YoY amid generic...
Bio-Techne Corp (TECH) Q3 2026 Earnings Call Transcript
Bio-Techne reported flat Q3 revenue of $295.9 million, with a 2% foreign‑exchange gain offset by a 2% headwind from businesses held for sale. Adjusted operating margin expanded to 31.1%, up roughly 100 basis points year‑over‑year, while adjusted EPS rose 10%...
Taysha Gene Therapies Inc (TSHA) Q1 2026 Earnings Call Transcript
Taysha Gene Therapies announced that its Rett syndrome gene therapy TSHA-102 has moved into pivotal development, securing FDA Breakthrough Therapy designation and written alignment on both the REVEAL pivotal and ASPIRE trial designs. Early Phase 1/2 data showed a 100%...
Urogen Pharma Ltd (URGN) Q1 2026 Earnings Call Transcript
UroGen Pharma reported a $15.8 million 2025 revenue for its newly launched Zasturi, with the permanent J code effective Jan. 1 2026 spurring a sharp uptick in prescriber and site adoption. The company now has 838 activated sites, over 95% payer access, and...
Sarepta Therapeutics Inc (SRPT) Q1 2026 Earnings Call Transcript
Sarepta Therapeutics reported $1.86 billion net product revenue for 2025, a 16% increase, and ended the year with $954 million in cash and investments. Management guided 2026 net product revenue to $1.2‑$1.4 billion, emphasizing a low‑end outlook while targeting operating profit and positive...
Madrigal Pharmaceuticals Inc (MDGL) Q1 2026 Earnings Call Transcript
Madrigal Pharmaceuticals reported its Q1 2026 earnings, highlighting that Rezdiffra generated $958 million in net sales for its first full year, nearly $1 billion in total revenue. Patient enrollment rose to 36,250, reflecting strong sequential growth in the expanding MASH market. The...
Novavax Inc (NVAX) Q1 2026 Earnings Call Transcript
Novavax reported a Q1 2019 net loss of $43.2 million, improving from the prior year, while revenue fell 59% to $4 million as the Bill & Melinda Gates Foundation grant wound down. The company highlighted clinical milestones for its RSV vaccine ResVax,...
Quanterix Corp (QTRX) Q1 2026 Earnings Call Transcript
Quanterix Corp reported fourth‑quarter revenue of $43.9 million, a 25% year‑over‑year increase and 7% sequential growth, though organic revenue fell 22% as both Simoa and Spatial platforms declined over 20%. The company highlighted a $897 CMS reimbursement rate for its Lucent...
Expanding the Human Proteome with Microproteins and Peptideins
An international consortium led by the TransCODE project has established a rigorous workflow to annotate non‑canonical open reading frames (ncORFs) and their encoded microproteins as reference human proteins. By expanding the PeptideAtlas platform, the team analyzed billions of mass‑spectrometry spectra,...
Zevra Therapeutics Inc (ZVRA) Q1 2026 Earnings Call Transcript
Zevra Therapeutics reported Q1 2026 net revenue of $36.2 million, a 78% year‑over‑year increase, driven primarily by MyPlifer sales of $24.6 million and a $10.2 million expanded‑access program. The company completed the $50 million divestiture of its SDX portfolio, recorded a $43.3 million one‑time gain...
Mineralys Therapeutics Inc (MLYS) Q1 2026 Earnings Call Transcript
Mineralys Therapeutics reported Q1 2026 results highlighting FDA acceptance of lorundrostat’s NDA with a PDUFA target of Dec 22, 2026. The company completed five trials showing durable blood‑pressure reductions, though the EXPLORER‑OSA study missed its primary AHI endpoint, it still demonstrated a...
Cytokinetics Scores Late-Stage Win in Non-Obstructive HCM as BMS Plans Camzyos Restart
Cytokinetics announced that its experimental drug Myqorzo (aficamten) achieved both primary endpoints in the Phase III ACACIA‑HCM trial, marking the first late‑stage success for a therapy targeting non‑obstructive hypertrophic cardiomyopathy (HCM). The result propelled the company’s stock up 17%, pushing its...
Scientists Map Genetic Switches on Mosquito Reproductive Genes, Advancing Tools to Fight Disease
Scientists at Keele University have produced the first detailed map of cis‑regulatory elements that govern reproduction in Anopheles gambiae, the primary malaria vector. The atlas identifies hundreds of genetic switches and the exact nucleotides that drive germline expression in both...
Advances in Genetic Medicine Took Center Stage at INSAR
At INSAR in Prague, researchers highlighted a surge of genetic‑medicine breakthroughs aimed at autism, focusing on rare variants such as SCN2A, SHANK3 and UBE3A. Techniques ranging from CRISPR gene editing to antisense oligonucleotides and epigenome editing demonstrated tangible symptom improvements,...
OTC Monograph Drug User Fee Amendments (OMUFA): Understanding FY 2026 User Fees and Registration - 05/05/2026
The FDA’s Center for Drug Evaluation and Research hosted a May 5, 2026 webinar to explain the Over‑the‑Counter Monograph Drug User Fee Amendments (OMUFA) for fiscal year 2026. The session covered fee structures, registration requirements for OTC monograph facilities, payment timelines, and penalties...
The BioPharm Brief: Breakthrough Biologics and Long-Term Wins in IBD and Beyond
Viridian Therapeutics reported positive Phase III REVEAL‑2 data for veligrotug (VRDN‑001) in chronic thyroid eye disease, showing statistically significant reductions in proptosis and higher overall response rates. Eli Lilly presented four‑year long‑term results for mirikizumab (Omvoh) in ulcerative colitis, with a substantial...
BofA Raises Cytokinetics Price Target on ACACIA Trial Results
Bank of America raised its price target for Cytokinetics (CYTK) to $83 from $67 while keeping a neutral rating. The move follows the company’s positive Phase 3 ACACIA‑HCM trial, where aficamten met both primary endpoints in non‑obstructive hypertrophic cardiomyopathy. CYTK shares...
Questions and Answers on Current Good Manufacturing Practice Regulations | Production and Process Controls
The FDA released a detailed Q&A clarifying current Good Manufacturing Practice (CGMP) expectations for pharmaceutical manufacturers. It addresses equipment labeling, warehouse sampling of containers, media‑fill contamination sources, and the number of validation batches required for new products. The guidance also...
First Patient Enrolled in Massive Heart Failure Trial
CVRx has begun enrolling patients in BENEFIT‑HF, a pivotal trial of its Barostim implant for heart failure. The study plans to enroll roughly 2,500 NYHA Class II‑III patients across the United States and Germany and will run through 2032. Participants must...
F.D.A. Blocked Publication of Research Finding Covid and Shingles Vaccines Were Safe
The U.S. Food and Drug Administration blocked publication of several agency‑conducted studies that found Covid‑19 and shingles vaccines to be safe. The withdrawn research, funded with public dollars, had been slated for peer‑review journals and a drug‑safety conference. FDA officials...
How AI Tools Could Enable Bioterrorism
Recent advances in generative AI are lowering the barrier for creating biological weapons. Large language models can now design DNA sequences that encode harmful pathogens, while cheap gene‑editing kits like CRISPR are readily purchasable online. The convergence of open‑source genetic...
Viridian Data Lift Prospects for Thyroid Eye Disease Drug
Viridian Therapeutics announced that its subcutaneous drug elegrobart met primary endpoints in a Phase 3 trial for chronic thyroid eye disease, showing 50%‑54% response rates versus 15% for placebo. The once‑monthly regimen also improved double vision in 61% of patients, while...
FDA Commissioner Defends Agency's Drug Approval Decisions After Wave of Backlash
FDA Commissioner Marty Makary faced intense media and political backlash after the agency rejected Replimune’s melanoma drug candidate. In a CNBC interview, Makary emphasized that three independent FDA panels reached the same safety conclusion and rejected accusations of bias toward...
Bio Korea 2026 Kicks Off with Spotlight on Oligonucleotides
In early May 2026, several biotech firms announced pivotal milestones. Axsome Therapeutics received FDA clearance for Auvelity (AXS‑05) to treat agitation in Alzheimer’s disease, a condition affecting up to 75% of patients. Sonire Therapeutics began its U.S. Sunrise II trial of...
This Hand-Held Cancer Probe Feels What Surgeons May Miss and Changes How Tumors Are Found in Real Time
Researchers from Australian universities and a Polish institute have created a wireless, hand‑held probe that uses optical elastography to differentiate cancerous from healthy tissue during breast‑conserving surgery. The device, called stereoscopic optical palpation (SOP), measures tissue stiffness and displays a...
Second Life for Gene Therapy; Takeda Phase 2/3 Win; UK Cancer Biotech's $83M
A Cleveland‑based biotech announced a revamped gene‑therapy platform that could give a previously stalled program a second chance, while Takeda disclosed positive Phase 2/3 results for its oncology candidate. Across the Atlantic, a UK cancer‑focused biotech raised roughly $83 million to accelerate...
ADAPT OCULUS Trial Shows Promising Results in Treatment Efficacy for Ocular MG: Carolina Barnett-Tapia, MD, PhD
The ADAPT OCULUS Phase III trial evaluated efgartigimod alfa (VYVGART) in patients with ocular myasthenia gravis (oMG). In a double‑blind, placebo‑controlled arm, participants receiving the drug showed statistically significant reductions in ptosis and diplopia versus placebo. An open‑label extension confirmed continued...
Genome Mining Unlocks the Chemistry of Biocontrol Fungi
Researchers at the Technical University of Denmark applied genome‑mining tools to 82 Hypocreales fungi, uncovering dozens of secondary metabolites, many of which are non‑ribosomal peptides. The study revealed both common small peptides and rare large 18‑member structures, and successfully linked...
Prolific Machines Sets Monoclonal Antibody (mAb) Manufacturing Record with Light-Controlled Platform
Prolific Machines, an SOSV portfolio company, announced a record 21 g/L monoclonal antibody titer in a 15‑day intensified fed‑batch CHO run using its light‑controlled optogenetic platform. The photomolecular system lets operators toggle gene expression in real time with light, offering reversible,...
Emcure Doubling Down on Biosimilars Pipeline: MD Satish Mehta
Emcure Pharmaceuticals is expanding its biosimilars pipeline as a wave of biologic patent expiries creates market tailwinds. The company currently sells six biosimilars through its Gennova Biopharmaceuticals subsidiary and will now seek external partners to bring additional products to India...
Study Surveys Dysfunctional Gene Splicing in Metastatic Kidney Disease
Researchers at City of Hope and its TGen division found that a tumor’s “splicing burden” – the frequency of aberrant gene‑splicing events – strongly correlates with clinical response in metastatic renal cell carcinoma (mRCC). By RNA‑sequencing 101 patient samples, they...
Rebecca Crews Talks About Getting New Parkinson’s Disease Treatment
Rebecca King Crews, a Parkinson’s disease patient and fashion entrepreneur, underwent MRI‑guided focused ultrasound thalamotomy in July 2025 and reported rapid symptom relief. The FDA expanded the device’s indication in July 2025 to allow staged bilateral treatments, which Crews completed...
STAT+: Are Analysts Too Quick to Gloss over Lilly’s Liver Case?
Analysts are being criticized for downplaying a recent liver safety issue at Eli Lilly, raising concerns about market oversight. Meanwhile, biotech earnings showed mixed results, with Vertex shelving an mRNA cystic fibrosis candidate and Pfizer and Alkermes delivering near‑consensus Q1 numbers....
Viridian Reports Positive Phase III REVEAL-2 Data for Elegrobart in Chronic Thyroid Eye Disease
Viridian Therapeutics announced that its subcutaneous IGF‑1R antibody elegrobart met the primary endpoint in the phase 3 REVEAL‑2 trial for chronic thyroid eye disease (TED). Patients receiving the drug every four or eight weeks showed 50‑54% proptosis responder rates and 55‑61%...
5 Key April FDA Approvals Signal Momentum Across Rare, Chronic Diseases
April 2026 saw five FDA approvals spanning HIV, type 1 diabetes, chronic spontaneous urticaria, genetic hearing loss, and systemic lupus erythematosus. Merck’s Idvysno introduced the first tenofovir‑free, non‑INSTI two‑drug HIV regimen, while Sanofi’s teplizumab received clearance for children as young as...
Ruby Bio Reports Fermentation Breakthrough for Clean-Label Emulsifiers as Pressure on Synthetics Mounts
Ruby Bio announced that its fermentation platform achieved titers exceeding 100 g per liter for lipid‑based natural emulsifiers, a level the company says meets cost parity with synthetic alternatives. The breakthrough comes as health researchers, retailers and regulators push synthetic emulsifiers...
Key Biosimilars Events of April 2026
In April 2026 the biosimilar landscape saw a wave of regulatory approvals and strategic deals. The European Commission cleared Poherdy (pertuzumab) and Tuyory (tocilizumab), while Health Canada and China’s NMPA approved multiple denosumab biosimilars and granted IND clearances for Henlius’...
Foundayo’s Liver Failure Blip Weighs Down Lilly Shares but Analysts Unconcerned
A single hepatic failure case linked to Eli Lilly’s new weight‑loss pill Foundayo appeared in the FDA’s adverse‑event database, prompting a brief sell‑off that pushed the stock down about 3% before rebounding to close up 0.48%. Lilly quickly investigated and...
CareFusion 213, LLC - 722729 - 04/30/2026
The FDA issued Warning Letter 320‑26‑72 to CareFusion 213, LLC, a BD subsidiary, citing extensive CGMP violations at its El Paso sterile drug facility. Inspectors documented over 2,500 customer complaints involving foreign particles, missing components, and compromised seals, and found the company’s investigations,...